Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-101 in Adults with Major Depressive Disorder
2025-522784-15-00Phase 2Authorised
- Sponsor
- Draig Therapeutics
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing DT-101 with Placebo (2 arms). Primary endpoint: Change in MADRS score. Planned start Mar 2026; status: authorised.
02
Drugs
DT-101
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-522784-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522784-15-00.